Evidence map›Paper›PMID 29659728›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018

Racial Disparities in Invasive Methicillin-resistant Staphylococcus aureus Infections, 2005-2014.

Nicole Gualandi, Yi Mu, Wendy M Bamberg, Ghinwa Dumyati, Lee H Harrison, Lindsey Lesher, Joelle Nadle, Sue Petit, Susan M Ray, William Schaffner and 3 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Impact of Methicillin Resistance on Outcomes ofOpen forum infectious diseases · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Epidemiology, length of stay, and survival outcomes ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025
    Article
  10. Article
  11. Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000-2021.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  12. Review
  13. Quantifying racial disparities in risk of invasiveInfection control and hospital epidemiology · 2024
    Article
  14. Different evolution ofHeliyon · 2024
    Article
  15. Article
  16. Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024
    Article
  17. National partnerships address critical needs in infection prevention and control.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024
    Article
  18. Estimating the Burden of Clinically SignificantOpen forum infectious diseases · 2023
    Article
  19. Article
  20. Black and White Patients With Staphylococcus aureus Bacteremia Have Similar Outcomes but Different Risk Factors.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 1 country.

Nicole GualandiDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Yi MuDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Wendy M BambergColorado Department of Public Health and Environment, Denver.
Ghinwa DumyatiNew York-Rochester Emerging Infections Program and University of Rochester Medical Center.
Lee H HarrisonJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Lindsey LesherMinnesota Department of Health, St. Paul, Oakland.
Joelle NadleCalifornia Emerging Infections Program, Oakland.
Sue PetitConnecticut Department of Public Health, Hartford.
Susan M RayGeorgia Emerging Infections Program and Emory University School of Medicine, Decatur.
William SchaffnerVanderbilt University Medical Center, Nashville, Tennessee.
John TownesOregon Health & Science University, Portland.
Mariana McDonaldOffice of Health Disparities, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Isaac SeeDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Centers for Disease Control and Prevention · USColorado Department of Public Health and Environment · USConnecticut Department of Public Health · USEmory University · USIbis Reproductive Health · USJohns Hopkins University · USMinnesota Department of Health · USNational Center for Emerging and Zoonotic Infectious Diseases · USOregon Health & Science University · USVanderbilt University Medical Center · US

Funding

Emerging Infections Program-HAIU01CI000311 · CI · NYSDOH/HEALTH RESEARCH, INC. · PI BIRKHEAD, GUTHRIE S · 2005 to 2011
$25.8M
Colorado Emerging Infections Program-ARRA-HAIU01CI000305 · CI · COLORADO STATE DEPT/PUB HLTH &ENVIRONMT · PI GERSHMAN, KEN A. · 2005 to 2011
$11.8M
Intramural CDC HHS CC999999NCEZID CDC HHS U50 CK000195NCEZID CDC HHS U50 CK000196NCEZID CDC HHS U50 CK000197NCEZID CDC HHS U50 CK000198NCEZID CDC HHS U50 CK000201NCEZID CDC HHS U50 CK000203NCEZID CDC HHS U50 CK000204NCPDCID CDC HHS U01 CI000305NCPDCID CDC HHS U01 CI000311
6 · The paper itself

Abstract

Background: Despite substantial attention to the individual topics, little is known about the relationship between racial disparities and antimicrobial-resistant and/or healthcare-associated infection trends, such as for methicillin-resistant Staphylococcus aureus (MRSA). Methods: We analyzed Emerging Infections Program 2005-2014 surveillance data (9 US states) to determine whether reductions in invasive MRSA incidence (isolated from normally sterile body sites) affected racial disparities in rates. Case classification included hospital-onset (HO, culture >3 days after admission), healthcare-associated community onset (HACO, culture ≤3 days after admission and dialysis, hospitalization, surgery, or long-term care residence within 1 year prior), or community-associated (CA, all others). Negative binomial regression models were used to evaluate the adjusted rate ratio (aRR) of MRSA in black patients (vs in white patients) controlling for age, sex, and temporal trends. Results: During 2005-2014, invasive HO and HACO (but not CA) MRSA rates decreased. Despite this, blacks had higher rates for HO (aRR, 3.20; 95% confidence interval [CI], 2.35-4.35), HACO (aRR, 3.84; 95% CI, 2.94-5.01), and CA (aRR, 2.78; 95% CI, 2.30-3.37) MRSA. Limiting the analysis to chronic dialysis patients reduced, but did not eliminate, the higher HACO MRSA rates among blacks (aRR, 1.83; 95% CI, 1.72-1.96), even though invasive MRSA rates among dialysis patients decreased during 2005-2014. These racial differences did not change over time. Conclusions: Previous reductions in healthcare-associated MRSA infections have not affected racial disparities in MRSA rates. Improved understanding of the underlying causes of these differences is needed to develop effective prevention interventions that reduce racial disparities in MRSA infections.

Indexed as

Health Status DisparitiesMethicillin-Resistant Staphylococcus aureusRace FactorsAdolescentAdultAgedBlack or African AmericanBlack PeopleChildChild, PreschoolCommunity-Acquired InfectionsCross InfectionEpidemiological MonitoringFemaleHospitalizationHumans

Identifiers

PMID29659728
PMCPMC6232852
OpenAlexW2582489268

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.